Gmax

TARGET TECHNOLOGIES INTERNATIONAL INC. INTRODUCES REVOLUTIONARY NEW INFILL

Retrieved on: 
Tuesday, September 12, 2023
Gmax, Maintenance, HIC, Temperature, Absorption, J. E. M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., West Shore School District, AAA, Longevity, Safety

VANCOUVER, BC, Sept. 12, 2023 /PRNewswire/ -- Target Technologies International Inc. (TTII), announced today that the company has been named the exclusive distributor of NATURE'S INFILL™. This American-grown, sustainable, high-performance infill is made from organic corn material and delivers benefits unsurpassed in the industry.

Key Points: 
  • VANCOUVER, BC, Sept. 12, 2023 /PRNewswire/ -- Target Technologies International Inc. (TTII), announced today that the company has been named the exclusive distributor of NATURE'S INFILL™.
  • This American-grown, sustainable, high-performance infill is made from organic corn material and delivers benefits unsurpassed in the industry.
  • John B. Giraud, managing director of TTII, commented "This is a revolutionary infill that delivers on safety, performance, durability, and sustainability.
  • When we recognized the multiple benefits of Nature's Infill, we quickly realized it was a game changer and wanted to be the exclusive distributor of this specialty infill product."

GMAX Zhengzhou Manufacturing Site Breaks Ground

Retrieved on: 
Tuesday, December 15, 2020
Application software, BioPharm, Clinical data management, Computational biology, Distributed data storage, Software, 3D graphics software, Computing, Gmax, Hangzhou

HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.

Key Points: 
  • HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between 2023-2025, upon approval of respective clinical trials.
  • Our modern facility enables us to have direct control on product delivery," says Dr. Jing, GMAX Biopharm CEO.
  • GMAX completed phase 1b/2a trial in 2020 and plan to start phase III trial in China in 2021.
  • About Gmax Biopharm LLC: Gmax is a clinical stage company established in 2010 and headquartered in Hangzhou, China.